Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinic...
January 16 2014 - 7:55AM
Business Wire
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an
FDA-approved optical diagnostic device that assists dermatologists
in the diagnosis of melanoma, will host its third company-sponsored
Clinical Advisory meeting for select dermatologists and key opinion
leaders in melanoma and provide recent clinical findings at the
Winter Clinical Dermatology Conference being held January 17-22 at
the Fairmont Orchid Hotel, Kona Coast, Hawaii.
MELA Sciences’ Clinical Advisory meeting, for current and
prospective MelaFind® users and thought leaders, will
discuss technical advancements for the MelaFind® device as
well as opportunities for future technology development for the
Company’s optical imaging and analysis technologies. Dr. Darrell
Rigel, Clinical Professor of Dermatology at New York University
Medical Center, will moderate the meeting and Dr. Monica Scheel of
Kailua Kona, HI will present her real world experience with
MelaFind® and discuss its integration into her practice.
The Winter Clinical is expected to have over 400 dermatologists
in attendance. Practicing dermatologists will engage in
comprehensive updates and dialogue on the diagnosis and treatment
of a variety of medical, surgical and appearance dermatology
conditions led by leading dermatologists from the U.S. and
Canada.
MELA Sciences will exhibit four poster presentations focused on
the use of MelaFind®, its multispectral digital skin lesion
analysis tool. The posters review clinical data from practice and
clinical settings, using MelaFind® in the assessment of
pigmented skin lesions in a variety of patients including young
adults and those with atypical mole syndrome.
According to the Melanoma Research Foundation people under 30
are developing melanoma at an alarming rate, with the incidence
rising by 50% in young women since 1980. It is the most common form
of cancer for young adults aged 25-29 and the second most common
cancer in adolescents and young adults aged 15-29.
MelaFind® is the first and only FDA-approved and CE
Mark-approved optical imaging device for use by dermatologists in
the detection and analysis of melanoma. The Cleveland Clinic
recognized it as a Top 10 Medical Innovation for 2013. Click here
for additional information about MelaFind®.
Please follow us:
Twitter:
@MELASciencesIR or @MelaFind
StockTwits:
@MELASciencesIR
Facebook:
www.facebook.com/MelaFind
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
flagship product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
MediaMELA Sciences, Inc.Diana Garcia Redruello,
212-518-4226dgarcia@melasciences.comorInvestorsCatalyst
GlobalToni Trigiani, David Collins,
212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024